证券代码：000423 证券简称：东阿阿胶 公告编号：2025-65 东阿阿胶股份有限公司 关于对外捐赠的公告 为推动中医药科技赋能与产业升级，拟与上海中医药大学进行校企合作。本 次校企合作聚焦于胶类药物及膏方研究、国际标准制定、人才培养、中医药文化 传承创新等方面。基于本次合作，为激励学生勤奋学习、潜心科研，拟在上海中 医药大学设立"东阿阿胶奖学金"。合作期五年，公司每年向校方提供奖学金 15 万元，总金额 75 万元。根据《深圳证券交易所股票上市规则》《公司章程》 等相关规定，本议案无需提交股东大会审议。 本次捐赠事项不涉及关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 二、对公司的影响 本次对外捐赠，彰显公司作为行业领军企业对中医药文化传承创新的责任担 当，有助于加速科技创新与产品升级，提升行业标准，构建人才储备与创新生态。 该捐赠事项，对公司本期及未来财务状况和经营成果不构成重大影响，不影响公 司正常生产经营活动。 三、备查文件 特此公告。 东阿阿胶股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东阿阿胶股份有限 ...

关于董事辞职的公告 证券代码：000423 证券简称：东阿阿胶 公告编号：2025-58 东阿阿胶股份有限公司 公司将根据相关法律法规规定，尽快完成董事及董事会下设委员会委员补选 等工作。 公司董事会对王小跃女士、于晓辉女士在任职期间为公司发展做出的贡献表 示衷心感谢！ 特此公告。 二〇二五年十一月十三日 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东阿阿胶股份有限公司（以下简称"公司"）董事会近日收到王小跃女士、 于晓辉女士提交的书面辞职报告，由于工作变动原因，王小跃女士申请辞去公司 第十一届董事会董事职务，第十一届董事会战略委员会、薪酬与考核委员会委员 职务；于晓辉女士申请辞去公司第十一届董事会董事职务，第十一届董事会战略 委员会、审计委员会委员职务。辞职后，王小跃女士、于晓辉女士不再担任公司 及公司控股子公司任何职务；王小跃女士、于晓辉女士将继续在华润医药集团有 限公司任职。 根据《公司法》《公司章程》等相关法律法规规定，王小跃女士、于晓辉女 士的辞职不会导致公司董事会成员低于法定最低人数，不会影响公司董事会的正 常运作，辞职报告自送达董事会之日起生 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-63 东阿阿胶股份有限公司 2026 年度日常关联交易预计公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 东阿阿胶股份有限公司（以下简称"公司"或"东阿阿胶"）于 2025 年 11 月 12 日召开第十一届董事会第十四次会议，以 6 票同意、0 票反对、0 票弃权的 表决结果，审议通过了《关于预计 2026 年度日常关联交易额的议案》，预计 2026 年本公司及子公司与关联方发生的与日常经营相关联的交易总额不超过 117,036 万元，2025 年 1-9 月，实际发生额为 60,736 万元（数据未经审计）。 关联董事程杰先生对本项议案进行了回避表决。本议案提交董事会前已经公 司独立董事专门会议全体成员同意并发表相关意见。 此项关联交易尚须获得股东大会的批准，关联股东华润东阿阿胶有限公司、 华润医药投资有限公司将回避表决。 （二）预计日常关联交易类别和金额 预计 2026 年本公司及子公司与关联方发生的与日常经营相关联的交易总额 不超过 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-61 东阿阿胶股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东阿阿胶股份有限公司（以下简称"公司"）第十一届董事会第十四次会议， 于 2025 年 11 月 12 日审议通过了《关于修订<公司章程>的议案》。 现将有关情况公告如下： 一、基本概述 根据《公司法》的相关规定，结合公司实际情况，本次《公司章程》修订经 股东大会审议通过后，公司将不再设置监事会和监事，由董事会审计委员会行使 《公司法》规定的监事会的职权，公司《监事会议事规则》相应废止，公司各项 制度中涉及监事会、监事的规定不再适用。 二、《公司章程》具体修订情况 为进一步提升公司规范运作水平，完善公司治理结构，根据《公司法》《上 市公司章程指引》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件的相关规定，结合公司实际情况，对《公司章程》相关条款进行修订。 本次修订内容主要包括完善总则、法定代表人、股 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-64 东阿阿胶股份有限公司 关于增补董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东阿阿胶股份有限公司（以下简称"公司"）第十一届董事会第十四次会议， 于 2025 年 11 月 12 日审议通过了《关于增补董事的议案》。 依照《公司法》《公司章程》等相关规定，经董事会提名委员会审核，公司 董事会同意控股股东提名王毅飞女士为公司第十一届董事会非独立董事候选人 （简历附后），任期自股东大会审议通过之日起至第十一届董事会任期届满之日 止。该事项需提交公司 2025 年第一次临时股东大会审议通过后生效。 本次增补董事完成后，公司董事会中兼任高级管理人员的董事人数，总计未 超过公司董事总数的二分之一。 特此公告。 董 事 会 二〇二五年十一月十三日 附：董事候选人简历 王毅飞：女，1980 年 12 月出生，持有中国药科大学理学学士及沈阳药科大 学理学硕士学位，高级工程师。曾任中国医药研究开发中心有限公司分析室研发 人员、技术部经理、生产部经理、质量总监、项目管理部负责人，华润医药控股 有限 ...

Core Insights - The announcement of the ninth batch of national-level manufacturing single champion enterprises includes two companies from Liaocheng: Dong'e Ejiao Co., Ltd. and Xinpengyuan (Liaocheng) Intelligent Technology Co., Ltd. [1] - National-level manufacturing single champion enterprises are defined as companies that focus on specific segments of the manufacturing industry, maintain a leading global market share, possess strong innovation capabilities, and achieve high quality and efficiency [1] - Liaocheng has been focusing on the industrial economy as a top priority, continuously increasing efforts to cultivate manufacturing single champion enterprises through a combination of gradient cultivation and precise services [1] Company and Industry Development - As of now, Liaocheng has cultivated a total of 9 national-level manufacturing single champion enterprises [1] - The city is enhancing its cultivation system by following the principle of "reserving a batch, cultivating a batch, and improving a batch," and is actively identifying and selecting potential "quasi-champions" with core technologies and high market shares [1] - A manufacturing single champion enterprise cultivation database has been established, currently housing 90 companies, with a focus on monitoring, evaluation, and dynamic management services tailored to industry characteristics and company traits [1] Future Plans - The Liaocheng Industrial and Information Technology Bureau will continue to strengthen cultivation efforts, improve the gradient cultivation system, and promote the gradual growth of more distinctive quality enterprises into single champion enterprises [1] - This initiative aims to accumulate new momentum for the development of the manufacturing industry and support the high-quality development of the city's industrial economy [1]

Core Viewpoint - The announcement of the ninth batch of national-level manufacturing single champion enterprises highlights the recognition of companies that excel in specific manufacturing sectors, showcasing their global market leadership and innovation capabilities [1] Group 1: National-Level Manufacturing Single Champion Enterprises - Two companies from Liaocheng, Dong'e Ejiao Co., Ltd. and Xinpengyuan (Liaocheng) Intelligent Technology Co., Ltd., have been selected as national-level manufacturing single champion enterprises [1] - National-level manufacturing single champion enterprises are defined as those that focus on specific segments of the manufacturing industry, maintain a leading global market share, possess strong innovation capabilities, and achieve high quality and efficiency [1] Group 2: Liaocheng's Manufacturing Development Strategy - Liaocheng has been focusing on the industrial economy as a top priority, continuously increasing efforts to cultivate manufacturing single champion enterprises through a combination of gradient cultivation and precise services [1] - The city has successfully nurtured a total of nine national-level manufacturing single champion enterprises to date [1] - Liaocheng is enhancing its cultivation system by following the principle of "reserving a batch, cultivating a batch, and improving a batch," and has established a cultivation database for potential single champion enterprises [1] Group 3: Future Plans - The Industrial and Information Technology Bureau of Liaocheng will continue to strengthen cultivation efforts, improve the gradient cultivation system, and promote the growth of more distinctive quality enterprises into single champion enterprises [1] - The aim is to accumulate new momentum for the development of the manufacturing industry and support high-quality industrial economic growth in the city [1]

Core Viewpoint - The Chinese traditional medicine sector, particularly the Chinese Medicine ETF (560080), is experiencing increased investor interest due to favorable market conditions and relatively low valuations, with a notable inflow of funds and positive performance in recent trading sessions [1][3][10]. Group 1: Market Performance - On November 10, the Shanghai Composite Index rose by 0.53%, with the consumer sector leading gains, particularly the Chinese medicine segment, which saw the Chinese Medicine ETF (560080) increase by 1.55% and a trading volume exceeding 160 million yuan [1]. - The Chinese Medicine ETF (560080) has seen a cumulative net inflow of over 260 million yuan in the past 20 days, bringing its total fund size to over 2.8 billion yuan, leading its peers significantly [1][3]. Group 2: Valuation Insights - As of November 7, the TTM price-to-earnings (PE) ratio of the Chinese Medicine ETF (560080) was 25.31, placing it at the 24.5% percentile over the past decade, indicating that the index is cheaper than 75% of the time historically [3]. - The TTM PE ratio is just 0.57 away from the calculated opportunity value, suggesting a higher cost-performance ratio for potential investors [3]. Group 3: Stock Performance - Most constituent stocks of the Chinese Medicine ETF (560080) showed positive performance, with notable gains from Yunnan Baiyao, Pianzaihuang, and Yiling Pharmaceutical, all rising over 2%, while others like Tongrentang and Dong'e Ejiao also saw increases [5][6]. Group 4: Industry Trends - The Chinese medicine index has shown negative returns year-to-date, with a decline of 0.24% this year and an 8.13% drop in 2024, indicating a challenging market environment [7]. - Despite recent struggles, analysts suggest that the sector may be approaching a turning point, with potential improvements in performance expected due to rising flu incidence and better management of inventory levels among leading OTC Chinese medicine companies [10][11]. Group 5: Institutional Insights - Analysts from Zheshang Securities highlight that the Chinese medicine industry has characteristics similar to the banking sector, with strong cash flow and stable profit growth, suggesting resilience against external shocks [11]. - The industry is expected to see improved revenue growth in the second half of 2025, driven by declining raw material prices and cost-cutting measures by companies [11].

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]

Core Insights - Recently, China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes venture capital, specifically limited to investments in unlisted companies [1] - The fund is jointly funded by several companies, including Fosun Pharma, Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical [1] Company Contributions - Fosun Pharma's wholly-owned subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is a key contributor to the fund [1] - Other contributors include Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical, indicating a collaborative investment approach among major players in the pharmaceutical industry [1] Investment Focus - The fund is specifically focused on venture investments, which suggests a strategic interest in supporting early-stage pharmaceutical companies [1] - The emphasis on unlisted companies may provide opportunities for high-growth potential investments within the pharmaceutical sector [1]